Similar articles

• Quantitative conformational analyses predict distinct receptor sites for PCP-like and sigma drugs.

  Manallack DT, Beart PM. Manallack DT, et al. Eur J Pharmacol. 1987 Dec 1;144(2):231-5. doi: 10.1016/0014-2999(87)90524-3. Eur J Pharmacol. 1987. PMID: 2830125
• Biochemical and behavioral effects of sigma and PCP ligands.

  Contreras PC, Contreras ML, O'Donohue TL, Lair CC. Contreras PC, et al. Synapse. 1988;2(3):240-3. doi: 10.1002/syn.890020311. Synapse. 1988. PMID: 2850629
• The novel anticonvulsant MK-801: a potent and specific ligand of the brain phencyclidine/sigma-receptor.

  Sircar R, Rappaport M, Nichtenhauser R, Zukin SR. Sircar R, et al. Brain Res. 1987 Dec 1;435(1-2):235-40. doi: 10.1016/0006-8993(87)91606-4. Brain Res. 1987. PMID: 2827853
• Phencyclidine (PCP) and phencyclidine-like compounds: a molecular graphics-molecular mechanics study.

  Carroll F, Brine G, Mascarella S. Carroll F, et al. NIDA Res Monogr. 1988;90:122-8. NIDA Res Monogr. 1988. PMID: 2855851 Review.
• Neuropeptide Y receptors: autoradiographic distribution in the brain and structure-activity relationships.

  Quirion R, Martel JC, Dumont Y, Cadieux A, Jolicoeur F, St-Pierre S, Fournier A. Quirion R, et al. Ann N Y Acad Sci. 1990;611:58-72. doi: 10.1111/j.1749-6632.1990.tb48922.x. Ann N Y Acad Sci. 1990. PMID: 2174224 Review. No abstract available.